McKesson (MCK) Tops Q1 EPS by 2c, Revenues Miss; Offers FY19 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
McKesson (MCK) PT Lowered to $134 at Baird; Remains Sidelined
July 27, 2018 7:15 AM EDTBaird lowered its price target on McKesson (NYSE: MCK) to $134.00 (from $141.00) while maintaining a Neutral rating. MCK claims in-line performance across all three segments. However, YY EBIT facts: U.S. +2% on easy/transitory prior-year comparison, EU -12%, Med-Surg flat, Other -8%. Three of... More
Pharma's middlemen see shares suffer as challenges grow
July 25, 2018 12:04 PM EDTBy Lewis Krauskopf
NEW YORK (Reuters) - Uncertainty over potential actions to reduce prescription drug costs and competitive threats have taken a toll this year on shares of companies in the U.S. pharmaceutical supply chain. They get their chance to change investor sentiment with quarterly earnings reports in the coming days.
Prescription drug wholesalers, drug store chains and pharmacy benefit managers generally have seen their stock prices tumble this year, even as the overall S&P 500 healthcare sector has gained 6 percent.
Six S&P 500 stocks - CVS Health Corp (NYSE:... More
